Last reviewed · How we verify
hypoglycemic Agents(metformin)
hypoglycemic Agents(metformin) is a Biguanide Small molecule drug developed by First Affiliated Hospital of Wenzhou Medical University. It is currently FDA-approved for Type 2 diabetes mellitus, Prediabetes (off-label or prevention studies).
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, thereby lowering blood glucose levels in type 2 diabetes.
Metformin is a small molecule hypoglycemic agent used to treat Type 2 Diabetes Mellitus, as indicated by its study in various clinical trials on ClinicalTrials.gov. Its mechanism of action is not specified in the provided facts, but it is classified as a small molecule according to ChEMBL.
At a glance
| Generic name | hypoglycemic Agents(metformin) |
|---|---|
| Sponsor | First Affiliated Hospital of Wenzhou Medical University |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing glucose uptake and utilization in muscle and adipose tissue. It does not stimulate insulin secretion, making it weight-neutral and useful in combination with other agents. The drug may also improve insulin sensitivity through activation of AMP-activated protein kinase (AMPK) and modulation of mitochondrial function.
Approved indications
- Type 2 diabetes mellitus
- Prediabetes (off-label or prevention studies)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare, in renal impairment)
Key clinical trials
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy (PHASE4)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (PHASE1, PHASE2)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin (PHASE3)
- Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hypoglycemic Agents(metformin) CI brief — competitive landscape report
- hypoglycemic Agents(metformin) updates RSS · CI watch RSS
- First Affiliated Hospital of Wenzhou Medical University portfolio CI
Frequently asked questions about hypoglycemic Agents(metformin)
What is hypoglycemic Agents(metformin)?
How does hypoglycemic Agents(metformin) work?
What is hypoglycemic Agents(metformin) used for?
Who makes hypoglycemic Agents(metformin)?
What drug class is hypoglycemic Agents(metformin) in?
What development phase is hypoglycemic Agents(metformin) in?
What are the side effects of hypoglycemic Agents(metformin)?
What does hypoglycemic Agents(metformin) target?
Related
- Drug class: All Biguanide drugs
- Target: All drugs targeting AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
- Manufacturer: First Affiliated Hospital of Wenzhou Medical University — full pipeline
- Therapeutic area: All drugs in Endocrinology / Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Prediabetes (off-label or prevention studies)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing